Niraparib is a new cancer drug currently being assessed to see if it can be made available to women through the NHS. Target Ovarian Cancer has been invited to represent the views of women living with ovarian cancer in Scotland.
Thank you to everyone who took the time to share their thoughts and experiences regarding access to ovarian cancer drug treatments. We have submitted our response to the Scottish Medicines Consortium (SMC) and used what you told us throughout. In June 2018 we will participate in the Patient and Clinician Engagement (PACE) group meeting, representing the views of women with ovarian cancer and their families and carers.
We will share further information as it becomes available.
A separate process has taken place in England where the National Institute for Health and Care Excellence (NICE) has approved the use of niraparib in England on the Cancer Drugs Fund. The Welsh Government has also funded the use of niraparib through its New Treatment Fund.